NKGen Biotech raises $1M gross from convertible notes; warrants at $2.00

NKGen Biotech, Inc.

Total gross proceeds of $1M from three convertible promissory notes to Meteora ($200k), Alpha ($500k), and AJB ($300k).
Aggregate principal amount $1.21M; notes mature in 12 months; convertible at $2.00 per share.
Warrants issued to purchase up to 1.1M shares at $2.00 per share for five years.
Alpha and AJB have options to require additional notes and warrants worth up to $2.96M and 2.64M shares.
Notes include original issue discounts; Meteora Note bears 12% interest; others zero coupon.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NKGen Biotech, Inc. entered into Meteora Purchase Agreement with Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Captial, LLC (collectively, "Meteora") valued at $220,000 (effective 2024-05-07).

Action: entry
Agreement: equity purchase
Counterparty: Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Captial, LLC (collectively, "Meteora")
Value: $220,000
Effective: 2024-05-07

Exact text from the filing

On May 7, 2024, the Company issued a 12% promissory note (the “ Meteora Note ”) in the principal amount of $220,000, pursuant to a Securities Purchase Agreement (the “ Meteora Purchase Agreement ”), by and among Meteora Select Trading Opportunities Master, LP, Meteora Capital Partners, LP and Meteora Strategic Captial, LLC (collectively, “ Meteora ”) and the Company.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NKGen Biotech, Inc. entered into AJB Purchase Agreement with AJB Capital Investments LLC ("AJB") valued at $369,600 (effective 2024-05-09).

Action: entry
Agreement: equity purchase
Counterparty: AJB Capital Investments LLC ("AJB")
Value: $369,600
Effective: 2024-05-09

Exact text from the filing

On May 9, 2024, the Company entered into to a Securities Purchase Agreement (the “ AJB Purchase Agreement ”), by and between AJB Capital Investments LLC (“ AJB ”) and the Company.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NKGen Biotech, Inc. entered into Alpha Purchase Agreement with Generating Apha Ltd. ("Alpha") valued at $616,000 (effective 2024-05-07).

Action: entry
Agreement: equity purchase
Counterparty: Generating Apha Ltd. ("Alpha")
Value: $616,000
Effective: 2024-05-07

Exact text from the filing

On May 7, 2024, the Company issued a zero coupon promissory note (the “ Alpha Note ”) in the principal amount of $616,000, pursuant to a Securities Purchase Agreement (the “ Alpha Purchase Agreement ”), by and between Generating Apha Ltd. (“ Alpha ”) and the Company.

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001213900-24-041708

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.